BioPorto (BIOPOR) - Net Assets

Latest as of September 2025: Dkr35.18 Million DKK ≈ $5.50 Million USD

Based on the latest financial reports, BioPorto (BIOPOR) has net assets worth Dkr35.18 Million DKK (≈ $5.50 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr68.09 Million ≈ $10.65 Million USD) and total liabilities (Dkr32.91 Million ≈ $5.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BioPorto (BIOPOR) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Dkr35.18 Million
% of Total Assets 51.67%
Annual Growth Rate N/A
5-Year Change -32.83%
10-Year Change 52.36%
Growth Volatility 92.72

BioPorto - Net Assets Trend (1999–2024)

This chart illustrates how BioPorto's net assets have evolved over time, based on quarterly financial data. Also explore BioPorto assets under control for the complete picture of this company's asset base.

Annual Net Assets for BioPorto (1999–2024)

The table below shows the annual net assets of BioPorto from 1999 to 2024. For live valuation and market cap data, see BIOPOR stock market capitalisation.

Year Net Assets Change
2024-12-31 Dkr67.78 Million
≈ $10.60 Million
+12.66%
2023-12-31 Dkr60.16 Million
≈ $9.41 Million
-14.33%
2022-12-31 Dkr70.22 Million
≈ $10.99 Million
+52.77%
2021-12-31 Dkr45.96 Million
≈ $7.19 Million
-54.45%
2020-12-31 Dkr100.91 Million
≈ $15.79 Million
+298.52%
2019-12-31 Dkr25.32 Million
≈ $3.96 Million
-54.94%
2018-12-31 Dkr56.20 Million
≈ $8.79 Million
+0.23%
2017-12-31 Dkr56.07 Million
≈ $8.77 Million
+26.59%
2016-12-31 Dkr44.29 Million
≈ $6.93 Million
-0.44%
2015-12-31 Dkr44.48 Million
≈ $6.96 Million
+55.08%
2014-12-31 Dkr28.69 Million
≈ $4.49 Million
-33.07%
2013-12-31 Dkr42.86 Million
≈ $6.71 Million
+3827.13%
2012-12-31 Dkr-1.15 Million
≈ $-179.93K
-129.19%
2011-12-31 Dkr3.94 Million
≈ $616.44K
+19.07%
2010-12-31 Dkr3.31 Million
≈ $517.72K
-78.53%
2009-12-31 Dkr15.41 Million
≈ $2.41 Million
-0.59%
2008-12-31 Dkr15.50 Million
≈ $2.43 Million
-47.37%
2007-12-31 Dkr29.45 Million
≈ $4.61 Million
+267.21%
2006-12-31 Dkr-17.62 Million
≈ $-2.76 Million
-476.44%
2005-12-31 Dkr-3.06 Million
≈ $-478.13K
-104.56%
2004-12-31 Dkr66.97 Million
≈ $10.48 Million
+0.59%
2003-12-31 Dkr66.58 Million
≈ $10.42 Million
+3151.10%
2002-12-31 Dkr-2.18 Million
≈ $-341.39K
-293.15%
2001-12-31 Dkr-555.00K
≈ $-86.83K
-162.08%
2000-12-31 Dkr894.00K
≈ $139.87K
+418.15%
1999-12-31 Dkr-281.00K
≈ $-43.96K
--

Equity Component Analysis

This analysis shows how different components contribute to BioPorto's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 36084000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Dkr429.67 Million 633.94%
Other Comprehensive Income Dkr-1.05 Million -1.55%
Total Equity Dkr67.78 Million 100.00%

BioPorto Competitors by Market Cap

The table below lists competitors of BioPorto ranked by their market capitalization.

Company Market Cap
Media Prima Bhd
KLSE:4502
$96.08 Million
Wanbury Limited
NSE:WANBURY
$96.08 Million
Bridgemarq Real Estate Services Inc
TO:BRE
$96.12 Million
Prozone Realty Limited
NSE:PROZONER
$96.17 Million
ALT5 Sigma Corporation
NASDAQ:ALTS
$96.02 Million
New Delhi Television Limited
NSE:NDTV
$95.95 Million
Panda Financial Holding Corp Ltd
SHG:600599
$95.95 Million
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
$95.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BioPorto's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 60,160,000 to 67,778,000, a change of 7,618,000 (12.7%).
  • Net loss of 68,243,000 reduced equity.
  • New share issuances of 81,400,000 increased equity.
  • Other comprehensive income decreased equity by 1,277,000.
  • Other factors decreased equity by 4,262,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Dkr-68.24 Million -100.69%
Share Issuances Dkr81.40 Million +120.1%
Other Comprehensive Income Dkr-1.28 Million -1.88%
Other Changes Dkr-4.26 Million -6.29%
Total Change Dkr- 12.66%

Book Value vs Market Value Analysis

This analysis compares BioPorto's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 7.42x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 Dkr-0.08 Dkr1.24 x
2006-12-31 Dkr-0.43 Dkr1.24 x
2007-12-31 Dkr0.56 Dkr1.24 x
2008-12-31 Dkr0.24 Dkr1.24 x
2009-12-31 Dkr0.24 Dkr1.24 x
2010-12-31 Dkr0.05 Dkr1.24 x
2011-12-31 Dkr0.05 Dkr1.24 x
2012-12-31 Dkr-0.02 Dkr1.24 x
2013-12-31 Dkr0.43 Dkr1.24 x
2014-12-31 Dkr0.19 Dkr1.24 x
2015-12-31 Dkr0.29 Dkr1.24 x
2016-12-31 Dkr0.27 Dkr1.24 x
2017-12-31 Dkr0.31 Dkr1.24 x
2018-12-31 Dkr0.28 Dkr1.24 x
2019-12-31 Dkr0.10 Dkr1.24 x
2020-12-31 Dkr0.47 Dkr1.24 x
2021-12-31 Dkr0.17 Dkr1.24 x
2022-12-31 Dkr0.21 Dkr1.24 x
2023-12-31 Dkr0.17 Dkr1.24 x
2024-12-31 Dkr0.17 Dkr1.24 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BioPorto utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -100.69%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -188.29%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 1.42x
  • Recent ROE (-100.69%) is above the historical average (-100.72%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 0.16% 4.99% 0.03x 1.21x Dkr-6.59 Million
2005 0.00% -360.20% 0.30x 0.00x Dkr-15.41 Million
2006 0.00% -305.82% 1.16x 0.00x Dkr-15.22 Million
2007 -51.76% -182.81% 0.25x 1.15x Dkr-18.19 Million
2008 -92.01% -171.03% 0.44x 1.24x Dkr-15.81 Million
2009 -104.33% -146.06% 0.54x 1.31x Dkr-17.62 Million
2010 -432.15% -103.61% 0.66x 6.34x Dkr-14.63 Million
2011 -378.32% -80.21% 0.87x 5.39x Dkr-15.30 Million
2012 0.00% -82.32% 0.98x 0.00x Dkr-14.59 Million
2013 -48.11% -124.05% 0.32x 1.21x Dkr-24.91 Million
2014 -45.06% -69.10% 0.50x 1.30x Dkr-15.79 Million
2015 -24.12% -52.65% 0.42x 1.10x Dkr-15.18 Million
2016 -51.48% -110.04% 0.41x 1.14x Dkr-27.23 Million
2017 -57.51% -128.18% 0.38x 1.17x Dkr-37.85 Million
2018 -67.70% -146.25% 0.39x 1.18x Dkr-43.67 Million
2019 -275.03% -261.60% 0.62x 1.69x Dkr-72.17 Million
2020 -61.01% -265.31% 0.17x 1.39x Dkr-71.65 Million
2021 -124.26% -235.48% 0.30x 1.77x Dkr-61.71 Million
2022 -108.12% -262.08% 0.27x 1.55x Dkr-82.95 Million
2023 -93.63% -181.95% 0.34x 1.49x Dkr-62.34 Million
2024 -100.69% -188.29% 0.38x 1.42x Dkr-75.02 Million

Industry Comparison

This section compares BioPorto's net assets metrics with peer companies in the Diagnostics & Research industry.

No peer company data available for comparison.

About BioPorto

CO:BIOPOR Denmark Diagnostics & Research
Market Cap
$96.05 Million
Dkr613.92 Million DKK
Market Cap Rank
#19333 Global
#82 in Denmark
Share Price
Dkr1.24
Change (1 day)
+9.73%
52-Week Range
Dkr0.84 - Dkr1.59
All Time High
Dkr7.78
About

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more